Dr. Cannon is a professor of medicine at Harvard Medical School, and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital. He earned his MD from Columbia University College of Physicians and Surgeons in New York and did internal medicine residency at Columbia Presbyterian Medical Center, and cardiovascular fellowship at Brigham and Women’s Hospital. Dr. Cannon has published over 1000 original articles, reviews, or electronic publications in the field of acute coronary syndromes and prevention and has authored or edited 17 books. He has received numerous awards, including leadership awards from the American College of Cardiology and the American Heart Association. As a senior investigator of the TIMI Study Group, he has been principal investigator of more than 15 multicenter clinical trials, including TACTICS-TIMI 18 and PROVE IT, and the IMPROVE IT trial. Dr. Cannon now serves as Executive Director of Cardiometabolic Trials at the Harvard Clinical Research Institute (HCRI). He is leading the RE-DUAL PCI trial, studying novel anticoagulant strategies in patients with atrial fibrillation undergoing stenting, and collaborates on many other trials and registry projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids and prevention.

Brian is a cardiologist and genetic epidemiologist who was educated and trained at Yale, Harvard, Oxford and Cambridge Universities. He is currently the Benjamin Meaker Visiting Professor in the Institute for Advanced Studies at the University of Bristol, UK, Director of the Cardiovascular Genomic Research Centre at Wayne State University School of Medicine in Detroit, and the Chief Medical and Scientific Officer of the US-Sino Collaboration working on the Chinese Precision Medicine Initiative in Beijing.  His research focuses on designing Mendelian randomization studies as ‘naturally randomized trials’ to generate naturally randomized evidence that can be used to improve the drug discovery and development process; inform the optimal design of randomized trials; fill evidence gaps when a randomized trial is not possible or practical; and define the practice of precision cardiovascular medicine.

Evan A Stein received his medical degree and PhD, from the University of Witwatersrand in Johannesburg, South Africa. He started the first lipid clinic in South Africa in 1972 and described the high gene frequency of Familial Hypercholesterolemia, especially in Afrikaners. He completed specialist training in Medical Biochemistry at McMaster University, Canada. From 1977-1987 he was on the full-time faculty at the University of Cincinnati, Ohio, as Professor of Pathology and Laboratory Medicine, and remained on faculty as Voluntary Professor until August of 2015.  In 1988 he founded Medical Research Laboratories and the Metabolic and Atherosclerosis Research Center, where he still serves as Director Emeritus. Dr Stein was a founding partner and Chief Scientific Officer in Medpace Inc, a global CRO. He currently serves on the board of CymaBay Therapeutics and the Scientific Advisory Boards of Catabasis Pharmaceuticals and Gemphire Pharmaceuticals.

Dr Stein has had a number of appointments to the National Institutes of Health since 1986, including the General Clinical Research Centers Advisory Committee, NCEP Lipid Standardization Committee, Data and Safety Advisory Board of the NHLBI Program on Genetics in Hypertension from 1999-2003and served a 5 year term on the FDA Clinical Chemistry and Clinical Toxicology Advisory Panel. 

His clinical research focuses on preventive cardiology and treatment of lipid disorders, and he was one of the earliest investigators with statins, apheresis, ezetimibe, MTP inhibitors, squalene synthase inhibitors and most recently PCSK9 inhibitors. Dr Stein has authored or co-authored more than 295 publications related to lipid metabolism and laboratory medicine. 

David Preiss is Associate Professor in the Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, and a clinical lipidologist based at the Churchill Hospital in Oxford. His major interest is the prevention of cardiovascular disease with particular focus on lipid modification and diabetes. With regard to PCSK9 inhibitor therapy, he was an investigator on the GAUSS-3 trial and has published other original research and reviews on this topic. He is a member of the Writing Group on the ongoing AHA statement on statin safety, co-author on a major review of statin safety published in the Lancet in 2016 and has led various meta-analyses of major randomized statin trials combining published and unpublished data. He was awarded the University of Glasgow’s Bellahouston Medal in 2012. He is currently Chief Investigator for the NIHR funded LENS study, a streamlined randomized trial investigating the effect of fenofibrate on the progression of diabetic eye disease.

r. C. Michael White, Pharm.D., FCP, FCCP received his B.S. in Pharmacy in 1994 and his Doctor of Pharmacy degree in 1996 from the Albany College of Pharmacy.  He completed a Fellowship in Cardiovascular Outcomes Research at Hartford Hospital and the University of Connecticut (UConn) in 1998.  Dr. White joined the faculty at the UConn School of Pharmacy in 1998 and in 2008 was appointed a Full Professor of Pharmacy Practice.   He was named the Department Head of Pharmacy Practice in July 2011 and continues in that role.

Dr White has been the Director of an Agency for Healthcare Research and Quality Evidence-based Practice Center since 2007, one of only 13 designated centers in North America. His 325 publications, 8786 citations, and an H-index of 50 place him within an elite group of researchers [https://scholar.google.com/citations?user=lWAD9d8AAAAJ]. His work has been published in JAMA, Lancet, Annals of Internal Medicine and Circulation with research coverage by NBC Nightly News, Good Morning America, BBC, CNN and other international media outlets.  He is an ACCP Young Investigator of the Year, AACP Lyman Award Winner, five time ASHP Foundation Drug Therapy Research Award, and recipient of the ASHP Award for Sustained Contributions to the Literature.  Dr. White’s research interests are in the areas of atherosclerosis, arrhythmias, and preventing adverse cardiovascular events from drugs, devices, herbs, and illicit substances.  He is a Fellow of the American Colleges of Clinical Pharmacy and Pharmacology and is a University Teaching Fellow, the highest teaching award at UConn.  He has a weekly TV segment on Fox61 in Connecticut where he shares medical news with the general public.  

Naveed Sattar is a clinically active academic experienced in epidemiology, biomarkers and trials investigating the causes and consequences of diabetes, obesity and heart disease. He has published over 650 papers has received several national and international prizes for his research, and is amongst the most highly cited clinical academics in the world according to Thomson Reuters in 2016. 

He has been on several guideline committees and is currently involved in several lifestyle and drug trials in diabetes and cardiovascular disease and leads on biomarker initiatives in several of these. He is also on Editorial or International advisory boards for Diabetologia, Lancet Diabetes and Endocrinology, BMC Medicine and UK Biobank, and is an Associate Editor for Circulation.  

Max Korman is a health economist out of the University of Oslo, where he specialized in health economic modeling and health economic evaluations and worked on modeling the cost-effectiveness of PCSK9 inhibitors in a Norwegian setting. Currently he works in the Norwegian Ministry of Local Government with the revenue system used to fund municipal-level welfare services in the country, including primary health care, kindergarten, and schools.